LMWH traditionally was recommended for venous thromboembolism (VTE) treatment in cancer patient. Recent JAMA article that enrolled 671 patients between 2016 and 2020 found DOACs are non inferior to LMWH for preventing recurrent VTE over 6-month follow-up .